Gilead Sciences, Inc. $GILD Shares Purchased by E. Ohman J or Asset Management AB

E. Ohman J or Asset Management AB lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 22.0% during the 4th quarter, Holdings Channel reports. The fund owned 396,125 shares of the biopharmaceutical company’s stock after buying an additional 71,478 shares during the quarter. Gilead Sciences comprises 1.1% of E. Ohman J or Asset Management AB’s portfolio, making the stock its 16th largest holding. E. Ohman J or Asset Management AB’s holdings in Gilead Sciences were worth $48,620,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Trivium Point Advisory LLC boosted its stake in Gilead Sciences by 1.1% during the third quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company’s stock worth $813,000 after buying an additional 83 shares during the period. Binnacle Investments Inc grew its holdings in shares of Gilead Sciences by 11.8% in the third quarter. Binnacle Investments Inc now owns 785 shares of the biopharmaceutical company’s stock valued at $87,000 after purchasing an additional 83 shares in the last quarter. Hemington Wealth Management grew its stake in shares of Gilead Sciences by 9.3% in the third quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock worth $110,000 after acquiring an additional 85 shares in the last quarter. Ignite Planners LLC grew its stake in Gilead Sciences by 1.1% during the 3rd quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock worth $880,000 after purchasing an additional 86 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. grew its stake in Gilead Sciences by 0.3% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 34,711 shares of the biopharmaceutical company’s stock worth $3,912,000 after purchasing an additional 87 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $137.34 on Tuesday. The company has a market cap of $170.50 billion, a price-to-earnings ratio of 20.29, a PEG ratio of 1.80 and a beta of 0.36. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. The firm has a 50 day moving average price of $142.98 and a 200 day moving average price of $128.15. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. During the same quarter last year, the firm posted $1.90 earnings per share. Gilead Sciences’s revenue for the quarter was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be paid a dividend of $0.82 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date is Friday, March 13th. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. Gilead Sciences’s payout ratio is currently 48.45%.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Acquisition adds OM336 (gamgertamig), a BCMAxCD3 T‑cell engager designed for rapid, deep B‑cell depletion—strengthens Gilead’s inflammation/autoimmune pipeline and provides a near‑term clinical asset that could drive future revenue if successful. Gilead Sciences to Acquire Ouro Medicines (Business Wire)
• Positive Sentiment: Major media and wire coverage confirms deal size and strategic rationale, increasing market confidence around the transaction’s credibility and near‑term impact. Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion (WSJ) Gilead to buy biotech firm Ouro Medicines in over $2 billion deal (Reuters)
• Positive Sentiment: Analyst support: Bank of America maintained a Buy rating and $162 price target, citing HIV franchise momentum and product upside—analyst backing can bolster investor sentiment. Buy Rating on Gilead (TipRanks / BofA)
• Neutral Sentiment: Health care sector strength is supporting stocks broadly, providing incidental tailwinds to GILD alongside the M&A news. Gilead nears up to $2bn deal for autoimmune biotech (Yahoo Finance)
• Neutral Sentiment: Reported March short‑interest data appear anomalous (showing zero/share changes and NaN), suggesting no clear short‑position signal from the data release. No reliable market pressure evident from short interest.
• Negative Sentiment: Deal and clinical risk: the price (up to $2.18B) is material and the asset is clinical‑stage—clinical trial failure, integration costs, or disappointments on OM336’s commercial potential could weigh on the stock. Gilead nearing up to $2 billion buyout of Ouro Medicines (Reuters)

Insider Transactions at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 115,640 shares of the stock in a transaction that occurred on Friday, January 23rd. The stock was sold at an average price of $135.00, for a total transaction of $15,611,400.00. Following the sale, the chief executive officer directly owned 566,698 shares in the company, valued at approximately $76,504,230. This represents a 16.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $144.23, for a total value of $432,690.00. Following the completion of the sale, the chief financial officer owned 179,191 shares in the company, valued at $25,844,717.93. The trade was a 1.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 309,280 shares of company stock valued at $44,068,850 over the last ninety days. 0.27% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on GILD shares. Mizuho increased their target price on Gilead Sciences from $140.00 to $170.00 and gave the company an “outperform” rating in a report on Wednesday, February 18th. Oppenheimer increased their price target on shares of Gilead Sciences from $128.00 to $165.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 11th. Daiwa Securities Group increased their price objective on Gilead Sciences from $129.00 to $161.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Needham & Company LLC reaffirmed a “buy” rating and issued a $170.00 target price on shares of Gilead Sciences in a report on Monday, February 23rd. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a report on Thursday, January 22nd. Twenty-four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $157.62.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.